Skip to main content
All lobbying filings

Takeda Pharmaceuticals America, Inc.

Takeda Pharmaceuticals America, Inc. filed a Q1 report for Takeda Pharmaceuticals America Inc. on April 22, 2025.

Lobbying for Takeda Pharmaceuticals America Inc.

As filed: TAKEDA PHARMACEUTICALS AMERICA, INC. for TAKEDA PHARMACEUTICALS AMERICA INC.

All filings by Takeda Pharmaceuticals America, Inc. · Everything Takeda Pharmaceuticals America Inc. has reported

 Filing · LD-2 quarterly report Q1 report
Reporting period
1st Quarter 2025
Jan 1 - Mar 31 · Posted Apr 22, 2025
Expenses
$490,000
What this organization spent lobbying with its own staff. Reported using the LDA's own definitions (method A): the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.
Client based in
District of Columbia

Official filing document

 Government bodies contacted 3

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

 Lobbying activity 6
Budget/Appropriations

FY 2025 Budget Resolution - Pharmaceutical Related Provisions

Taxation/Internal Revenue Code

Tax incentive issues as they relate to proposed global supply chain bills Discussions related to the repeal of the BEAT - provisions related to orphan drug tax credits Administration's Global Tax Proposal General issues around 2025 Reconciliation/Inbound Concerns

Trade (domestic/foreign)

General intellectual property policy issues Issues related to proposed tariffs - all pharmaceutical related provisions

Defense

Discussions around Supply Chain implications

Medicare/Medicaid

Policies to enhance patient access to medicines in Medicaid including rebate, waiver policy and funding issues Policies to enhance patient access to medicines in Medicare Review of proposed rule regarding testing of Medicare part B prescription drug models Proposals related to amending the protected classes in Medicare Medicare payment proposals Medicare Drug Price Negotiation Program: Selected Drugs for Initial Price Applicability Year 2026 Discussions on biosimilars related to IRA Discussions on spillover related to the IRA Medicare Drug Price Negotiation Program: Selected Drugs for Initial Price Applicability Year 2027 Medicare Drug Price Negotiation Program: Selected Drugs for Initial Price Applicability Year 2028 Discussions on reforming the Inflation Reduction Act Discussions on treatment of small molecule drugs related to IRA H.R.1 492 , S. 832, EPIC Act of 2025 H.R. 946, Optimizing Research Progress Hope and New (ORPHAN) Cures Act

Health Issues

Clarifying or reforming the 340B program Value-based drug contracting Patient access of plasma therapies Global pharmaceutical supply chain operations and manufacturing locations Most Favored Nation/International Reference Pricing Co-pay accumulators maximizers, alternate funding models Customs Border Protection changes impacting southern border plasma collections Promoting the Congressional Plasma Caucus Rare disease diagnosis and access to care Pharmacy Benefit Managers (PBMs) Drug pricing, including House and Senate draft bills H.R. 1476, S. 694, PLASMA Act H.R. 2528, Association Health Plans Act H.R. 2214, DRUG Act

 Bills named in this filing 7

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.

Report a problem